Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.04
RAD's Cash to Debt is ranked higher than
51% of the 567 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.49 vs. RAD: 0.04 )
RAD' s 10-Year Cash to Debt Range
Min: 0   Max: 0.13
Current: 0.04

0
0.13
Equity to Asset -0.25
RAD's Equity to Asset is ranked lower than
52% of the 566 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.41 vs. RAD: -0.25 )
RAD' s 10-Year Equity to Asset Range
Min: -0.38   Max: 0.41
Current: -0.25

-0.38
0.41
Interest Coverage 1.70
RAD's Interest Coverage is ranked lower than
51% of the 430 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 12.83 vs. RAD: 1.70 )
RAD' s 10-Year Interest Coverage Range
Min: 0.02   Max: 6.47
Current: 1.7

0.02
6.47
F-Score: 7
Z-Score: 3.43
M-Score: -2.50
WACC vs ROIC
34.56%
19.63%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 2.91
RAD's Operating margin (%) is ranked higher than
75% of the 569 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.36 vs. RAD: 2.91 )
RAD' s 10-Year Operating margin (%) Range
Min: -8.84   Max: 6.04
Current: 2.91

-8.84
6.04
Net-margin (%) 1.25
RAD's Net-margin (%) is ranked higher than
70% of the 569 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.16 vs. RAD: 1.25 )
RAD' s 10-Year Net-margin (%) Range
Min: -11.09   Max: 7.37
Current: 1.25

-11.09
7.37
ROA (%) 4.68
RAD's ROA (%) is ranked higher than
79% of the 571 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.10 vs. RAD: 4.68 )
RAD' s 10-Year ROA (%) Range
Min: -29.43   Max: 19.7
Current: 4.68

-29.43
19.7
ROC (Joel Greenblatt) (%) 20.70
RAD's ROC (Joel Greenblatt) (%) is ranked higher than
82% of the 570 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 18.27 vs. RAD: 20.70 )
RAD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -42.94   Max: 31.75
Current: 20.7

-42.94
31.75
Revenue Growth (3Y)(%) -3.00
RAD's Revenue Growth (3Y)(%) is ranked higher than
56% of the 485 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.40 vs. RAD: -3.00 )
RAD' s 10-Year Revenue Growth (3Y)(%) Range
Min: -16   Max: 19.6
Current: -3

-16
19.6
EBITDA Growth (3Y)(%) 24.50
RAD's EBITDA Growth (3Y)(%) is ranked higher than
95% of the 453 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.00 vs. RAD: 24.50 )
RAD' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -84.3   Max: 24.5
Current: 24.5

-84.3
24.5
» RAD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

RAD Guru Trades in Q1 2014

Jim Simons 1,593,000 sh (New)
George Soros 2,043,700 sh (New)
Paul Tudor Jones 2,104,420 sh (+2212.55%)
Ray Dalio 1,085,900 sh (+720.17%)
Ken Fisher 12,100 sh (+5.22%)
Jeremy Grantham Sold Out
Pioneer Investments Sold Out
John Burbank 26,509 sh (-14.94%)
John Hussman 1,000,000 sh (-16.67%)
David Einhorn 5,511,246 sh (-54.53%)
Steven Cohen 1,126,005 sh (-76.41%)
Joel Greenblatt 158,445 sh (-83.8%)
» More
Q2 2014

RAD Guru Trades in Q2 2014

Pioneer Investments 15,803 sh (New)
Andreas Halvorsen 13,458,963 sh (New)
Joel Greenblatt 3,163,882 sh (+1896.83%)
Jim Simons 5,364,888 sh (+236.78%)
George Soros 2,300,000 sh (+12.54%)
John Hussman 1,000,000 sh (unchged)
David Einhorn Sold Out
Ken Fisher 10,350 sh (-14.46%)
John Burbank 10,922 sh (-58.8%)
Ray Dalio 233,800 sh (-78.47%)
Paul Tudor Jones 54,449 sh (-97.41%)
» More
Q3 2014

RAD Guru Trades in Q3 2014

Steven Cohen 3,364,900 sh (New)
Ray Dalio 2,124,000 sh (+808.47%)
Joel Greenblatt 12,788,466 sh (+304.2%)
John Burbank 39,265 sh (+259.5%)
Ken Fisher 10,350 sh (unchged)
Andreas Halvorsen Sold Out
Jim Simons Sold Out
George Soros Sold Out
Paul Tudor Jones 54,400 sh (-0.09%)
John Hussman 500,000 sh (-50%)
» More
Q4 2014

RAD Guru Trades in Q4 2014

Louis Moore Bacon 1,150,000 sh (New)
NWQ Managers 206,300 sh (New)
Paul Tudor Jones 108,474 sh (+99.4%)
Ray Dalio 2,487,194 sh (+17.1%)
Ken Fisher 10,850 sh (+4.83%)
John Burbank Sold Out
John Hussman Sold Out
Joel Greenblatt 3,434,880 sh (-73.14%)
Steven Cohen 79,200 sh (-97.65%)
» More
» Details

Insider Trades

Latest Guru Trades with RAD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-12-31 Reduce -73.14%0.45%$4.51 - $7.56 $ 7.9844%3434880
John Hussman 2014-12-31 Sold Out 0.21%$4.51 - $7.56 $ 7.9844%0
NWQ Managers 2014-12-31 New Buy0.02%$4.51 - $7.56 $ 7.9844%206300
NWQ Managers 2014-12-31 New Buy0.02%$4.51 - $7.56 $ 7.9844%206300
John Burbank 2014-12-31 Sold Out $4.51 - $7.56 $ 7.9844%0
Joel Greenblatt 2014-09-30 Add 304.2%0.47%$4.95 - $7.57 $ 7.9824%12788466
Andreas Halvorsen 2014-09-30 Sold Out 0.42%$4.95 - $7.57 $ 7.9824%0
John Hussman 2014-09-30 Reduce -50%0.28%$4.95 - $7.57 $ 7.9824%500000
George Soros 2014-09-30 Sold Out 0.12%$4.95 - $7.57 $ 7.9824%0
Ray Dalio 2014-09-30 Add 808.47%0.07%$4.95 - $7.57 $ 7.9824%2124000
John Burbank 2014-09-30 Add 259.5%$4.95 - $7.57 $ 7.9824%39265
David Einhorn 2014-06-30 Sold Out 0.52%$6.05 - $8.5 $ 7.988%0
Andreas Halvorsen 2014-06-30 New Buy0.42%$6.05 - $8.5 $ 7.988%13458963
Joel Greenblatt 2014-06-30 Add 1896.83%0.27%$6.05 - $8.5 $ 7.988%3163882
Ray Dalio 2014-06-30 Reduce -78.47%0.04%$6.05 - $8.5 $ 7.988%233800
John Burbank 2014-06-30 Reduce -58.8%$6.05 - $8.5 $ 7.988%10922
David Einhorn 2014-03-31 Reduce -54.53%0.46%$5.04 - $6.92 $ 7.9832%5511246
George Soros 2014-03-31 New Buy0.13%$5.04 - $6.92 $ 7.9832%2043700
Joel Greenblatt 2014-03-31 Reduce -83.8%0.1%$5.04 - $6.92 $ 7.9832%158445
Ray Dalio 2014-03-31 Add 720.17%0.05%$5.04 - $6.92 $ 7.9832%1085900
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Rite Aid Corp

Joel Greenblatt: the Value Investment Magician's Most Recent Buys
Joel Greenblatt (Trades, Portfolio), founder of Gotham Asset Management, is a true value investor. He truly stands behind Warren Buffett (Trades, Portfolio)’s philosophy for buying stocks, which is to buy cheap stocks belonging to a good company. In order to figure out just how good a company is, Greenblatt looks at returns on tangible capital to fulfill his ultimate goal of finding something both cheap and good. Read more...
Weekly Insider Sells Highlight: RAD, KOS, SNDK, AFOP
According to GuruFocus Insider Data, the largest insider sells during the past week were: Rite Aid Corp., Kosmos Energy Ltd., SanDisk Corp., Crown Holdings Inc. and Alliance Fiber Optic Products Inc. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 24.80
RAD's P/E(ttm) is ranked higher than
76% of the 595 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 25.20 vs. RAD: 24.80 )
RAD' s 10-Year P/E(ttm) Range
Min: 3.17   Max: 6590
Current: 24.8

3.17
6590
Forward P/E 19.92
RAD's Forward P/E is ranked higher than
79% of the 595 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 19.88 vs. RAD: 19.92 )
N/A
PE(NRI) 24.90
RAD's PE(NRI) is ranked higher than
76% of the 595 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 25.80 vs. RAD: 24.90 )
RAD' s 10-Year PE(NRI) Range
Min: 3.18   Max: 219
Current: 24.9

3.18
219
P/S 0.31
RAD's P/S is ranked higher than
81% of the 595 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.57 vs. RAD: 0.31 )
RAD' s 10-Year P/S Range
Min: 0.01   Max: 0.32
Current: 0.31

0.01
0.32
PFCF 49.88
RAD's PFCF is ranked higher than
73% of the 595 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 41.27 vs. RAD: 49.88 )
RAD' s 10-Year PFCF Range
Min: 1.88   Max: 80.83
Current: 49.88

1.88
80.83
POCF 12.28
RAD's POCF is ranked higher than
76% of the 595 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 13.65 vs. RAD: 12.28 )
RAD' s 10-Year POCF Range
Min: 0.54   Max: 67
Current: 12.28

0.54
67
EV-to-EBIT 17.56
RAD's EV-to-EBIT is ranked higher than
74% of the 595 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 17.56 vs. RAD: 17.56 )
RAD' s 10-Year EV-to-EBIT Range
Min: -477   Max: 618
Current: 17.56

-477
618
Current Ratio 1.77
RAD's Current Ratio is ranked higher than
89% of the 569 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.15 vs. RAD: 1.77 )
RAD' s 10-Year Current Ratio Range
Min: 0.81   Max: 3.28
Current: 1.77

0.81
3.28
Quick Ratio 0.55
RAD's Quick Ratio is ranked higher than
66% of the 569 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.64 vs. RAD: 0.55 )
RAD' s 10-Year Quick Ratio Range
Min: 0.13   Max: 0.78
Current: 0.55

0.13
0.78
Days Inventory 58.91
RAD's Days Inventory is ranked higher than
64% of the 595 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 37.90 vs. RAD: 58.91 )
RAD' s 10-Year Days Inventory Range
Min: 59.45   Max: 129.21
Current: 58.91

59.45
129.21
Days Sales Outstanding 13.84
RAD's Days Sales Outstanding is ranked higher than
78% of the 595 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 16.82 vs. RAD: 13.84 )
RAD' s 10-Year Days Sales Outstanding Range
Min: 4.16   Max: 19.41
Current: 13.84

4.16
19.41

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 3.10
RAD's Price/Median PS Value is ranked higher than
52% of the 595 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.21 vs. RAD: 3.10 )
RAD' s 10-Year Price/Median PS Value Range
Min: 0.09   Max: 9.14
Current: 3.1

0.09
9.14
Price/Peter Lynch Fair Value 1.35
RAD's Price/Peter Lynch Fair Value is ranked higher than
94% of the 595 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.00 vs. RAD: 1.35 )
RAD' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.16   Max: 29.82
Current: 1.35

0.16
29.82
Earnings Yield (Greenblatt) 5.70
RAD's Earnings Yield (Greenblatt) is ranked higher than
73% of the 567 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.00 vs. RAD: 5.70 )
RAD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 10.3
Current: 5.7

0.2
10.3
Forward Rate of Return (Yacktman) 20.55
RAD's Forward Rate of Return (Yacktman) is ranked higher than
91% of the 451 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 8.43 vs. RAD: 20.55 )
RAD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -36.6   Max: 36.3
Current: 20.55

-36.6
36.3

Analyst Estimate

Feb15 Feb16 Feb17 Feb18
Revenue(Mil) 26,442 27,137 27,556 28,373
EPS($) 0.34 0.42 0.45 0.56
EPS without NRI($) 0.34 0.42 0.45 0.56

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers
Compare:SHDMF, APNHF, GNC, JCOUF, PMC » details
Traded in other countries:RTA.Germany,
Rite Aid Corp a Delaware corporation was incorporated on 1968. It operates retail drugstore chain in the United States. It operates its drugstores in 31 states across the country and in the District of Columbia. As of March 3, 2012, it operated 4,587 stores. The Company sells prescription drugs and an assortment of other merchandise, which it calls 'front end' products. Front end products include over-the-counter medications, health and beauty aids, personal care items, cosmetics, household items, food and beverages, greeting cards, seasonal merchandise and numerous other convenience products. The Company attempts to distinguish its stores from other national chain drugstores, in part, through its wellness + loyalty program, private brands and its strategic alliance with GNC, a retailer of vitamin and mineral supplements. The retail drugstore industry is competitive. It competes with retail drugstore chains, independently owned drugstores, supermarkets, mass merchandisers, discount stores, wellness offerings, dollar stores and mail order pharmacies. The Company's business is subject to federal, state, and local government laws, regulations and administrative practices.
» More Articles for RAD

Headlines

Articles On GuruFocus.com
Rite Aid Corporation is a Buy Feb 19 2015 
This Drugstore Retailer Should Have A Better 2015 Feb 12 2015 
My Picks Dec 18 2014 
Do Not be a Victim – Rite Aid Stock Study Dec 17 2014 
Are These Drugstore Retailers Good Investments? Dec 11 2014 
Rite Aid Corporation Looks Promising Dec 05 2014 
McKesson's Growth Is Set to Continue in the Long Run Nov 25 2014 
Joel Greenblatt: the Value Investment Magician's Most Recent Buys Nov 20 2014 
Why Rite Aid Continues To Look Attractive, Despite Some Fallouts Oct 17 2014 
Guru Joel Greenblatt Gives Back Oct 08 2014 

More From Other Websites
Catamaran EPS Tops, But Stock Falls On Weak Guidance Feb 26 2015
Rite Aid Announces First-Ever Innovation Challenge Feb 24 2015
Looking To Invest In the Third-Largest Pharmacy? Feb 23 2015
Rite Aid Announces Winners of 11th Annual Favorite Pharmacy Team Member Contest Feb 20 2015
Wal-Mart: Where the Challenges Are Feb 19 2015
Rite Aid to Acquire Leading Independent Pharmacy Benefit Manager EnvisionRx for $2 Billion Feb 19 2015
Zacks.com featured expert Kevin Matras highlights: Rite Aid, Advanced Semiconductor Engineering,... Feb 19 2015
Rite Aid Announces First-Ever Innovation Challenge Feb 19 2015
Rite Aid Contributes $590,000 to the United Way of the Capital Region in 2014 Feb 18 2015
Rite Aid Reports Same Store Sales for January Feb 18 2015
Rite Aid Opens First RediClinics Inside Select Rite Aid Pharmacies Feb 18 2015
Rite Aid Introduces Receutics Active Skin Repair Line Feb 16 2015
With purchase of EnvisionRx, Rite Aid gets in on the drug intermediary racket Feb 12 2015
How CVS turned its cigarette ban into a strategic weapon Feb 12 2015
Rite Aid (RAD) Jumps 6.6% on TPG's EnvisionRx Buyout - Analyst Blog Feb 12 2015
Rite Aid (RAD) Worth Watching: Stock Moves 6.6% Higher - Tale of the Tape Feb 12 2015
Cramer: Thanks Europe-good news for your portfolio Feb 11 2015
Rite Aid Stock Soars, Steps Up Competition With CVS Feb 11 2015
Envision Pharmaceutical Holdings, Inc. -- Moody's: Envision Pharmaceutical's ratings are unchanged... Feb 11 2015
Rite Aid buys pharmacy benefit manager EnvisionRx for $2 billion Feb 11 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK